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Summary
Surgery has historically been the standard of care for oper-
able stage I non-small cell lung cancer (NSCLC). However,
nearly one-quarter of patients with stage I NSCLC will not
undergo surgery because of medical comorbidity or oth-
er factors. Stereotactic ablative radiotherapy (SABR) is the
new standard of care for these patients. SABR offers high
local tumour control rates rivalling the historical results of
surgery and is generally well tolerated by patients with both
peripheral and centrally located tumours. This article re-
views the history of SABR for stage I NSCLC, summar-
ises the currently available data on efficacy and toxicity,
and describes some of the currently controversial aspects of
this treatment.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for around
85% of all lung cancers [1]. The preferred treatment of
stage I NSCLC is lobectomy with systematic mediastinal
lymph node evaluation [1]. However, nearly 25% of pa-
tients with stage I NSCLC will not undergo surgery, usually
because of poor lung function, frailty, comorbitidies or pa-
tient refusal [2]. For these patients there are various treat-
ment options including, usually, conventional fractionated
radiotherapy, but also chemotherapy, targeted therapy, radi-
ofrequency ablation, cryotherapy and observation. Histor-
ically, the efficacy of conventional fractionated radiother-
apy has been suboptimal, with local failure rates of 40%
[3], and an improvement in median survival time compared
with observation alone from 14 to 21 months, but only a
15% 5-year lung cancer-specific survival rate [2]. Recently,
substantial advances in the technology of radiation therapy
have led to promising treatment outcomes, in some cases
rivaling the historical results with surgery [4]. Indeed, loc-
al control rates of up to 92% have been reported in the lit-
erature [4]. This article reviews the history of stereotactic
ablative radiotherapy (SABR) for stage I NSCLC, summar-
ises the currently available data on efficacy and toxicity,
and describes some of the current controversial aspects of
this treatment.
Rationale for stereotactic ablative
radiotherapy for lung tumours
Stereotactic ablative radiotherapy (SABR) is a form of
high-precision radiotherapy that was originally developed
in the 1950s in order to accurately treat small intracranial
lesions with high biological doses of radiation. Technolo-
gical developments in image guidance, planning and deliv-
ery of radiation therapy in the last decade have led to the
application of this technique to extracranial sites, includ-
ing the thorax and abdomen [5]. Typically, SABR is de-
livered using in-room imaging (IGRT: image guided radi-
ation therapy) and 4D motion accommodation, to ensure
accurate dose delivery [6]. SABR delivery is characterised
by: (1.) reproducible and secure immobilisation to avoid
patient movement during long treatment sessions; (2.) rig-
orous accounting for organ motion; (3.) use of dose distri-
butions tightly covering the tumour by use of multiple (e.g.
≥10) or large-angle arcing small aperture fields, with rap-
id dose falloff in surrounding normal tissues in order to re-
duce toxicity; and (4.) most importantly, an ablative dose
in three to eight treatment fractions within a 2-week period
delivered to the patient with subcentimeter accuracy [7].
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Radiobiological aspects of SABR
The most widely accepted means of describing the rela-
tionship between radiation dose and cell survival for con-
ventionally fractionated radiotherapy is the linear-quadratic
formula [8]. Some have suggested that it is not applicable
to higher daily doses or smaller fraction numbers, and that
it overestimates the biological effect of large-dose fractions
[9, 10]. A few modifications have been proposed in order
to correct modelled SABR dose-response curves, such as
utilisation of the older multitarget model [11] or modifica-
tion of the existing linear-quadratic model by incorporation
of aspects of the lethal-potentially lethal model [12]. This
question has not been answered definitively and more re-
search is needed to model better high dose-fractional treat-
ments [13]. These include different radiobiological effects
of SABR, such as vascular and stromal effects that are not
seen with CFRT [14, 15], normal tissue effects, preserva-
tion of the immune response [16, 17], and the combination
of effective mechanisms with targeted drugs.
Another important aspect of SABR dose delivery relates
to the duration of the treatment session. Several authors
have argued that treatments sessions exceeding half an
hour might be associated with a clinically significant loss
in cytotoxicity [18, 19].
Immobilisation and target
reproducibility
Stable and reproducible patient positioning is essential.
This can be achieved with two systems:
– ‘‘Frame’’ systems: first reported by Lax and colleagues
[20], they provide both immobilisation and a fiducial
system that can approximate initial target localisation
independently of other image guidance systems (room
lasers and cone-beam computed tomography (CT)),
which is then enhanced and adjusted by means of
image-guided systems [20, 21]. These systems often
integrate a mechanical tool for reducing breathing
mobility, such as abdominal compression.
– ‘‘Frameless’’ systems: rely on the combination of
markers and image-guided systems (planar or
volumetric imaging and/or real-time tumour tracking)
to relocate a reference position within the patient
[22–24].
Both approaches provide similar reliability. Many recent
studies suggest the use of new image-guided systems cur-
rently available in conjunction with SABR may improve
the accuracy and precision of radiation delivery while po-
tentially obviating the need for stereotactic body frames
[23, 24].
The other important factor which has to be addressed is
breathing mobility. Because lung tumours can move up to 5
cm (especially for tumours near the diaphragm) [25, 26], it
is important that a method exists either to limit this motion
or to track the tumour and gate treatment delivery. There
are three general techniques to control tumour motion:
(1.) Reduction of tumour motion (dampening): abdominal
compression with an attached plate that is pressed
against the abdomen to reduce diaphragmatic
excursions [20, 24].
(2.) Administration of radiation within a particular portion
of the patient’s breathing cycle (expiration or
inspiration) (gating): utilises respiratory cycle
monitoring combined with a surrogate to trigger
delivery of radiation during a specific segment of the
respiratory cycle [27].
(3.) Tracking the tumour position (chasing): moving the
radiation beam path to follow the motion of the tumour
[28].
Regardless of motion control equipment, careful assurance
of high accuracy and reproducibility is essential for precise
treatment delivery.
Target definition
The gross tumour volume (GTV) is typically defined on
CT in lung windowing. The use of FDG PET-CT (FDG:
2-deoxy-[18F] fluoro-2-D-glucose; PET: positron emission
tomography) information in radiotherapy planning allows
better target volume definition, and reduces interobserver
variability [29]. Typically in SABR, the GTV is equal to
the clinical target volume (CTV) as no prophylactic treat-
ment is allowed, keeping the volume of normal tissues ex-
posed to high doses to a minimum [30]. The treatment
dose used might be high enough to treat possible extension,
through falloff of dose around the GTV. An internal target
volume (ITV) can also be delineated based on the volume
needed to encompass tumour motion. The margin from
CTV to PTV (planning target volume), which includes
setup uncertainty, will depend on the method of immob-
ilisation, the assessment of tumour motion, and the meth-
ods for setup and geometric verification [6, 31]. However,
because of similar geometric requirements with different
methods for SABR, a relatively narrow range of margins
between CTV and PTV is currently used in clinical prac-
tice. Margins generally used are 10 mm and 5 mm in the in
the cranial-caudal plane and transversal plane, respectively
[20, 24, 30, 32]. Normal tissues or organs at risk that must
be contoured include both lungs, heart, trachea and proxim-
al bronchi, distal bronchial tree, spinal canal, oesophagus,
and brachial plexus.
Treatment planning
SABR is characterised by a very steep dose falloff on the
margin of the target volume. This requires the use of mul-
tiple shaped beams (usually 10–15) or large angle arc rota-
tions [33–35]. Use of noncoplanar beams is encouraged to
avoid overlap of dose at points of entrance and exit [36].
Prescription isodose conformality to the target volume is
generally assessed with a conformality index, which is the
ratio of the prescription isodose volume to the PTV. Dose
deposited outside the PTV increases this ratio. This ratio
should be kept below 1.2 [37, 38]. Typical PTV coverage
should be 95% to 100% with 99% of the PTV covered by
90% of the prescription dose [37, 38]. Any areas receiv-
ing greater than 105% of the prescription dose, commonly
referred to as high-dose spillage, are generally confined to
the PTV [37, 38]. In many centres, prescription lines cover-
ing the PTV will typically be the 60% to 90% line, usually
80% (rather than 95%–100%); however, higher isodoses
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(hotspots) must be manipulated to occur within the target
and not in adjacent normal tissue [39–41]. Dose distribu-
tion of an SABR plan should satisfy three major criteria:
conformal high dose, compact intermediate dose and re-
spect of normal tissue dose-volume constraints. Reducing
high-dose spillage outside the intended treatment volume
is critical for preventing normal tissue toxicity in organs
at risk [37, 38]. Dose-volume relationships in the setting
of SABR are still ambiguous. These constraints are fre-
quently modified on the basis of patient outcome data in
ongoing multicentre trials evaluating SABR [42]. The dose
constraints for the organs at risk (including the spinal cord,
oesophagus, ispsilateral brachial plexus, heart, trachea, and
ipsilateral bronchus and whole lung) under the Radiation
Therapy Oncology Group (RTOG) protocol 0236 [32] are
shown in table 1.
Current results of SABR for medically
inoperable stage I NSCLC
Local control
Despite the use of a wide range of equipment, techniques
and fractionation schemes, nearly all published series of
SABR for medically inoperable stage I NSCLC report 85%
to 95% local control rates (summarised in table 2) [30, 32,
39, 43–46].
One of the first prospective trials was initiated by Indiana
University. This was a dose-escalation phase I study in pa-
tients with stage I medically inoperable NSCLC to assess
toxicity and local control rates [30]. Forty-seven patients
were treated with SABR escalating from a starting dose of
24 Gy over three fractions (3 x 8 Gy fractions) up to 72
Gy in three fractions (3 x 24 Gy fractions). Patients were
stratified into three dose escalation groups based on T stage
and tumour size. The maximum tolerated dose (MTD) was
66 Gy (3 x 22 Gy fractions) for T2 tumours larger than 5
cm (T2 >5 cm) and was not reached for T1 tumours at 60
Gy (3 x 20 Gy fractions) or T2 tumours less than 5 cm (T2
<5 cm) at 66 Gy (3 x 22 Gy fractions). At a median fol-
low up of 15.2 months, local failure had occurred in ten
patients, in nine at doses of 16 Gy or less and only one
at higher doses [29]. The same team conducted a phase II
trial that further evaluated efficacy and safety of SABR in
this patient population [39]. Doses established in the phase
I trial were used to treat 70 patients. With a median fol-
low up of 50.2 months, 3-year local control and survival
rates were 88.1% and 42.7%, respectively [39]. Similarly,
updated results from a phase II trial of SABR for medic-
ally inoperable stage I NSCLC in Scandinavia using 45 Gy
in three fractions showed 3-year local control and overall
survival rates of 92% and 60%, respectively, in 57 patients
with a median follow-up of 35 months [43].
Most recently, Timmerman et al. presented mature results
of the RTOG trial 0236 [32]. A total of 59 patients with
peripherally located medically inoperable stage I NSCLC
were accrued and 55 were evaluable (44 with T1 and 11
with T2 tumours). The prescribed dose was 54 Gy in three
fractions of 18 Gy. The 3-year tumour control rate was
97.6% at a median follow-up of 34.4 months. Only one
patient had a primary tumour failure [32]. In this same
context another recent prospective phase II trial was con-
ducted at the University of Torino. This trial included 62
patients with stage I NSCLC (43 with T1 and 19 with T2
disease) treated with SABR. The radiation dose was three
fractions of 15 Gy each (45 Gy). At a median follow-up
of 28 months, the 3-year local control and overall survival
rates were 87.8% and 57.1%, respectively, with 8 out of 20
noncancer related deaths [44]. Lagerwaard et al. from the
Netherlands evaluated outcomes of ‘‘risk-adapted’’ SABR
in 206 patients with stage I NSCLC of whom 81% were
medically inoperable. The decision process for the frac-
tionation schemes was customised on the basis of tumour
size and location [42]. Local control was greater than 90%
[45]. No randomised comparison between conventionally
fractionated radiotherapy and SABR for early NSCLC is
available, but a recent meta-analysis of observational stud-
ies revealed significantly superior 5-year overall survival
with SABR as opposed to conformal radiotherapy (42% vs
20%) [47]. Due to the large differences in both reported
local control rates and the number of fractions, randomisa-
tion in such a trial will prove challenging. In countries such
as the United States [48], Japan [49] and The Netherlands
[50], SABR gained wide acceptance for this indication.
Patterns of failure
After conventional radiotherapy, the locoregional recur-
rence rate in early stage NSCLC may be as high as 70% [3].
In contrast, distant metastases constitute the major problem
after SABR, a finding similar to that seen after surgery [32,
43, 45, 51–53].
RTOG 0236 reported only one patient with primary tumour
site failure (including marginal failure), with a 3-year
primary tumour control rate of 98%. Failure beyond the in-
volved lobe occurred in three other patients, giving a 3-year
local control rate of 91%. Regional failure within hilar or
mediastinal lymph nodes was quite low (two patients), des-
pite nonsurgical staging, giving a 3-year locoregional con-
trol rate of 87% [32]. Eleven patients failed in distant sites,
frequently within 1 year after SABR [32]. In a recent sys-
Table 1: Organ tolerance dose limits for Radiation Therapy Oncology Group study 0236a [32].
Organ Volume Dose (Gy)
Spinal cord Any point 18 Gy
Oesophagus Any point 27 Gy
Ipsilateral brachial plexus Any point 24 Gy (8 Gy / fraction)
Heart Any point 30 Gy (10 Gy / fraction)
Trachea and ipsilateral bronchus Any point 30 Gy (10 Gy / fraction)
Whole lung (right and left) <10% of volume 20 Gyb
a Exceeding organ limits by more than 2.5% constituted a “minor” protocol violation. Exceeding these organ limits by more than 5% constituted a “major” protocol violation.
b Also known as V20 or volume of total lung getting 20 Gy or more.
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tematic review of SABR for NSCLC studies, the main pat-
tern of failure after lung SABR was distant metastasis. This
occurred in 11% to 29% of patients in studies with ≥30
months of follow-up, but also in over 50% of patients in
some series [53]. Nodal recurrences occurred in approx-
imately 10% of patients in most studies (range 0%–23%)
[53]. Recurrences were associated with increased tumour
size [53].
One hypothesis to explain the low rates of regional recur-
rence after SABR might be that there was sufficient dose
falloff, related to the high biological dose radiotherapy, to
the regional nodes, and thus tumour cells in these nodes
may be sterilised [40]. Low regional recurrence rates can
also be explained by immune activity. Lee et al. demon-
strated that SABR substantially increases T-cell responses
in the draining lymphatic tissues in mice, leading to strong
anticancer cytotoxic activity; this effect is not seen after
standard low-dose conventionally fractionated radiother-
apy [16]. Because the risk of distant failure is significantly
higher for T2 tumours, some authors have advocated in-
vestigating the role of neoadjuvant chemotherapy in these
patients [43, 53]. The general failure pattern after SABR
underlines the importance of accurate lymph node staging
before therapy. PET/CT is the best noninvasive imaging
technique for the accurate determination of nodal status in
these patients, who are usually medically unfit for surgical
staging or not willing to undergo surgery [54]. The present
series included few patients without PET staging whose
outcome was not significantly inferior to PET/CT staged
patients [55].
Toxicity
Published reports of SABR for lung cancer describe a very
low acute and late toxicity rate compared with convention-
al radiation techniques in medically impaired patients, with
rates for grade 3 or higher toxicity being typically less than
4% [13, 32, 45, 56]. These low rates of toxicity are pre-
sumably due to both the precision of treatment delivery
and the structural physiology of lung tissue [57]. However,
the real risk of late toxicity may be underestimated, as
long-term follow-up has been limited owing to the relat-
ively high noncancer-related mortality in patients who are
usually medically unfit. In addition, symptoms of pulmon-
ary toxicity may be masked by exacerbations of coexisting
chronic obstructive pulmonary disease (COPD) and pneu-
monias.
Only a few investigators have carefully followed clinical
toxicity after SABR. The most commonly reported toxicit-
ies are radiation pneumonitis, oesophagitis, skin reactions,
chest wall pain and general malaise such as fatigue [58].
In general, the common side-effects are mild to moderate
(grade 1 to 2) and transient. The reported rate of grade
≥3 late toxicity was less than 10% in most studies [4, 45,
51–60]. Most of the accumulated grade 5 events have oc-
curred when patients received high-dose SBRT to centrally
located tumours adjacent to mediastinal organs [39, 51, 61,
62].
Table 2: Summary of the results of the prospective trials of stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
Trial Number of patients Stage Median
follow-up
(months)
Dose and
fractionation
Any toxicity ≥ grade 3.
n (%)
Local control Overall survival
Le QT et al. [61] 32 (20 primary
NSCLC)
T1‒2 N0 M0 18 15-30 Gy in 1 x 4 (12.5) 91% at 1 year for dose
≥25 Gy
85% at 1 year
Fakiris AJ
Et al. [39]
Phase II
70 T1‒2 N0 M0 50.2 60-66 Gy in 3 x 11 (15.7) 88.1% at 3 years 42.7% at
3 years
Timmerman R
(RTOG 0236) [32]
Phase II
55 T1‒2 N0 M0 34.4 60 Gy in 3 x 9 (16.3), no deaths 97.6% at 3 years 55.8% at 3
years
Lagerwaard Fj et
al. [45]
206 T1‒2 N0 M0 12 60 Gy in 3 x, 5 x or
8 x
6 (3) 93% at 2 years 64% at 2 years
Nagata Y et al. [84] 45 T1‒2 N0 M0 30 48 Gy in 4 x 0 (0) 98% at 2 years 82% at 3 years
Koto M et al. [46]
Phase II
31 T1‒2 N0 M0 32 45 Gy in 3 x, or 60 Gy
in 8 x
1 (3) T1: 77.9% at 2 years
T2: 40.0% at 2 years
71.7% at 3
years
Xia T et al. [85] 43 T1‒2 N0 M0
(25 patients)
T1‒2 N1 M0
27 50 Gy in 5 x 1 (2.3) 96% at 3 years 91% at 3 years
Taremi M et al. [86] 108 T1‒2 N0 M0 19.1 48 Gy in 4 x or
54–60 Gy in 3 x or
50–60 Gy in 8–10 x
Acute: 4 (3.7)
Late: 12 (11.1)
82% at 4 years 30% at 4 years
Bral S et al. [64] 40 T1–3 N0 M0 16 60 Gy in 3 or 4 x 8 (20) 84% at 2 years 52% at 2 years
Grills IS et al. [40] 124 (SBRT: 58,
Surgery: 69)
T1‒2 N0 M0 30 48 Gy in 4 x or
60 Gy in 5 x
6 (10.9) 7.2% at 2.5 years 72% at 2.5
years
Ricardi U et al. [44]
Phase II
62 T1‒2 N0 M0 28 45 Gy in 3 x 2 (3.2) 87.8% at 3 years 57.1% at 3
years
Baumann P et al.
[43]
Phase II
57 T1‒2 N0 M0 35 45 Gy in 3 x 17 (29.8) 92% at 3 years 60% at 3 years
Timmerman R et
al. [87]
Phase II
70 T1‒2 N0 M0 17.5 60-66 Gy in 3 x 14 (20) 95% at 2 years 54.7% at 2
years
x = fraction(s)
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As a result of the severe toxicity reported for central tu-
mours in the study at Indiana University [39] and other
trials, all central lesions have been excluded from RTOG
0236 [32]. An RTOG clinical study (RTOG 0813,
NCT00750269) is evaluating the use of different SABR re-
gimens to treat tumours located within the zone of the prox-
imal bronchial tree [63]. A risk-adapted approach has been
studied at VU University Medical Centre and the SABR re-
gimen varies according to tumour location [45]. Three frac-
tionation schemes were applied; three fractions of 20 Gy
(for T1 tumours), five fractions of 12 Gy (for T1 tumours
with broad contact with the thoracic wall, or T2 tumours)
or eight fractions of 7.5 Gy (for tumours adjacent to the
heart, hilus or mediastinum). This approach has yielded ac-
ceptable treatment-related toxicity in 206 patients [45].
Another prospective phase II, risk-adapted, SABR trial was
reported by Bral and colleagues from Belgium [64]. This
study included 40 patients with stage T1‒3N0M0 NSCLC
up to 6 cm in size, located both in the periphery (n = 23)
as well as in the central zone (n = 17), as defined by the
RTOG 0236 study [32, 64]. Peripheral tumours received 60
Gy in three fractions and central tumours received 60 Gy
in four fractions. With a median follow-up of 16 months,
the lung-toxicity-free survival estimate at 2 years was 74%,
and was related to the location (central vs peripheral) and
the size of the target volume. The 2-year local progression-
free survival (LPFS) and overall survival were 84% and
52%, respectively. The LPFS was significantly correlated
with the initial tumour stage (T1 vs T2, p = 0.006). The
dose reduction for central tumours did not increase the risk
of local failure. The authors concluded that the adapted
schedule did not lower the incidence of lung toxicity for
peripheral or central lesions (13.0% vs 29.4%), but it had
an impact on the severity of the toxicity. The pulmonary
toxicity was location-dependent even at low doses [64].
In addition to central tumour location, factors associated
with severe toxicity include fraction size [64, 65], and prior
treatment (radiotherapy or chemotherapy) [60]. For apical
tumours, when SABR is used there may be an increased
risk of injury to the brachial plexus. In a series of 36 pa-
tients with apical lesions treated with SABR at a median
dose of 57 Gy in three fractions, seven patients developed
grade 2, 3 or 4 brachial plexopathy [66]. These authors felt
that the tolerance of the major trunks of the brachial plexus
was around 26 Gy for a three-fraction regimen [66].
For peripheral lung tumours, chest-wall toxicity may be
manifested as rib fractures or pain [67, 68]. The incidence
of chest wall toxicity was illustrated by a series of 347
treated lesions, which included 203 on the chest wall. Both
chest-wall pain and rib fractures were more frequent when
chest-wall lesions, as compared with nonchest-wall lesions
were irradiated (16% vs 3% and 8% vs 1%, respectively)
[67]. Nevertheless, chest-wall toxicity after SABR occurs
less frequently than post-thoracotomy pain syndromes,
which can manifest in about 50% of surgical patients and
may persist up to 5 years after treatment (in up to 30% of
patients), although the more widespread use of video-assis-
ted thoracic surgery appears to have reduced this complic-
ation [69, 70].
SABR is an emerging treatment option in lung cancer
without long-term follow up. Constraints that are currently
being used in prospective trials are often based on a small
number of cases where the toxicity was observed, theoret-
ical equations and computer simulations. To ensure the best
possible understanding of the limits of safety of SBRT as
clinical practice evolves, it is of great importance that the
adverse radiation effects in individual clinical series be ad-
equately reported.
SABR for high-risk groups
SABR is an effective and safe treatment modality for high
surgical risk patients with early-stage NSCLC. Such high-
risk patients include elderly patients with low performance
status and severe comorbidity (e.g. severe COPD), and pa-
tients who have previously undergone lung resection or
thoracic irradiation [71].
Elderly patients are less likely to undergo surgery because
of comorbidities, functional deficits, poor performance
status and patient preference [50]. SABR studies did not
exclude these patients. The median age in these studies
ranged from 71 to 76 years, with three studies recruiting
patients in their 90s [59, 72, 73]. Despite this population
of elderly patients with comorbidities deemed unsuitable
for surgery, SABR was found to be well tolerated with
local control rates comparable to surgery. The most im-
portant side effect from SABR is pneumonitis, although
rates of grade 2 or more pneumonitis were typically less
than 5%. A potential limitation of SABR in the elderly is
the duration of each fraction, which can typically exceed
30 minutes. Some elderly patients, particularly those with
significant comorbidities, might find immobilisation on a
treatment table for this length of time intolerable. Volumet-
ric intensity-modulated arc therapy is currently being deve-
loped for use in SABR to allow a considerably shorter de-
livery time [74].
SABR was not shown to impair pulmonary function, al-
though patients with severe COPD constituted more than
one-third of treated individuals [43, 75, 76]. Data from
a single-institution cohort and a systematic literature re-
view produced a 1-year actuarial survival of 79% to 95%
and 3-year survival of 43% to 70% for SABR. Surgically
treated patients had an actuarial survival of 45% to 86% at
1 year and 31% to 66% at 3 years. No patient died within
30 days after SABR, whereas 10% of patients died after
surgery [77].
SABR has also been applied safely for recurrent or second
lung cancers in patients who have undergone previous
pneumonectomy or prior irradiation to the thorax [75, 78].
These factors take on increased importance if oncological
outcomes between SABR and surgery are equivalent. This
has prompted a cooperative group-sponsored prospective
randomised trial comparing the two treatments in high-risk
patients that has recently started accruing (American Col-
lege of Surgeons Oncology Group Z4099 / RTOG 1021)
[79].
SABR for operable early-stage NSCLC
Although there has been no direct comparison with surgery,
the results from observational studies suggest that the res-
ults with SABR for stage I NSCLC are similar to those
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of surgery. Onishi et al. have reported the largest series
(257 patients, 158 inoperable and 99 operable) and the
longest follow-up, with a 5-year overall survival of 47%,
a local failure rate of 13.5% and a regional failure rate
of 8.2% [59]. These authors make favourable comparisons
with groups of patients treated with standard surgery [59].
Others have reported local failure rates ranging from 3%
to 16% [30, 43, 45, 56]. Crabtree et al. compared short-
term outcomes with SABR and surgical resection for clin-
ical stage I NSCLC. Matched-patient analyses revealed no
differences between the groups in terms of overall surviv-
al, disease-specific survival or local control. No treatment-
related deaths occurred as a consequence of SABR. In the
surgery group, the operative mortality rate was 3.2% (15/
462) patients [56]. Grills et al. from William Beaumont
Hospital compared patients with stage I NSCLC who had
received treatment with either SABR or wedge resection,
and reported that rates of freedom from any failure, causes-
specific survival, distant metastasis, and local, regional,
and locoregional recurrence did not differ significantly
after a 30-month median follow-up, but the overall survival
rate was significantly higher in the surgery patients than in
those patients who had received SABR. No treatment-re-
lated deaths were observed as a consequence of either treat-
ment [40]. As with the results of Onishi et al. and Crabtree
et al., these results are provocative. However, again, these
studies are retrospective and uncontrolled, and subject to
many biases confounding interpretation.
These findings further underscore the importance of the
awaited international phase III trial conducted by the MD
Anderson Cancer Center (STARS trial, NCT00840749). In
this trial, 1,030 patients with T1 or T2 (<4 cm) NSCLC will
be randomly assigned to surgery or SABR (15 Gy x 4 frac-
tions or 20 Gy x 3 fractions for central and peripheral le-
sions, respectively). The primary endpoint is 3-year overall
survival [80]. A second European phase III trial (ROSEL
trial, NCT00687986) was terminated because of poor pa-
tient recruitment [81]. Other trials such as RTOG 0618 [82]
and JCOG 0403 (NCT00238875) [83], recently closed to
accrual, might shed furtherlight on this issue (table 3).
Conclusion
In summary, new technical refinements in delivery of
SABR have led to a widespread use of this technique. At
the present time SABR is firmly established as a standard-
of-care therapy for patients with early-stage inoperable
lung cancer. Although recent guidelines for the planning
and the execution of SABR for lung cancer have been pub-
lished [31], there is still much room for improvement. The
role of SABR in operable patients remains to be defined by
randomised trials (table 3).
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